Step Sequence Is a Critical Gait Parameter of Unilateral 6-OHDA Parkinson's Rat Models.
Parkinson's disease is a progressive neurological disorder, marked by the loss of dopaminergic neurons in the nigrostriatal pathway that leads to abnormal gait, rigidity, slowness of movement, and tremor. The ability to recapitulate and measure the neurological sequelae in rodent models of Parkinson's disease is important for studying and evaluating potential therapeutics. Individual variability in lesion severity and injury progression are key factors in the 6-hydroxydopamine model that require normalization when evaluating therapeutic effects. The gait parameters that were found to be affected by 6-hydroxydopamine lesioning of the nigrostriatal pathway in rats may be used to study novel transgenic models of Parkinson's disease as well as to test novel therapeutics. Previously, studies have used a video-based system to analyze gait abnormalities in the 6-hydroxydopamine model of Parkinson's disease, but these studies did not account for individual variability on reported gait parameters. By analyzing the ratio of parameters from the injured to uninjured sides and correcting for speed in related parameters, hindpaw step cycle parameters, hindpaw print area, and step sequence are significantly altered in different ways for each type of lesion, when compared to saline-injected controls. These findings enable new metrics for evaluating therapeutic efficacy of drug-, gene-, or cell-based therapies in rat models of Parkinson's disease.
Heather A
HA
Baldwin
Pyry P
PP
Koivula
Julie C
JC
Necarsulmer
Keith W
KW
Whitaker
Brandon K
BK
Harvey
D000818:Animals; D004195:Disease Models, Animal; D005684:Gait / Q000502:physiology*; D008124:Locomotion; D008297:Male; D008636:Mesencephalon / Q000378:metabolism / Q000473:pathology; D008694:Methamphetamine; D009474:Neurons / Q000473:pathology; D016627:Oxidopamine; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology*; D020318:Rats, Long-Evans; D012399:Rotation; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D008694:Methamphetamine; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase
Exp Neurol. 2002 Jun;175(2):303-17
12061862
Acta Physiol Scand Suppl. 1971;367:49-68
4332692
Behav Brain Res. 2012 Jan 15;226(2):519-28
22008381
Cell Tissue Res. 2004 Oct;318(1):215-24
15503155
Mov Disord. 2008 Nov 15;23(15):2129-70
19025984
BMC Neurosci. 2012 Nov 14;13:142
23151254
Med Clin North Am. 1999 Mar;83(2):327-47
10093581
Clin Biomech (Bristol, Avon). 2013 Jan;28(1):93-7
23062816
Brain Res. 1970 Dec 18;24(3):485-93
5494536
J Biomed Sci. 2010 Feb 13;17:9
20152049
Anat Rec (Hoboken). 2014 Oct;297(10):1839-64
24890845
Neurosci Lett. 2015 Jan 1;584:184-9
25449863